Molecularly-Targeted Therapeutic Strategies for Breast Cancer Focusing on HER2-Targeted Therapy, mTOR Inhibitor and Antiangiogenic Therapy
Pp. 157-228 (72)
Teruhiko Fujii, Keisuke Miwa, Tomoyuki Ushijima, Mototsugu Matsunaga, Masaru Fukahori, Kotaro Yuge, Uhi Toh, Nobutaka Iwakuma, Ryuji Takahashi, Hiroki Takahashi, Miki Takenaka, Mai Mishima, Yoshito Akagi, Masayoshi Kage, Shino Nakagawa and Maki Tanaka
The development of chemotherapy or endocrine therapy has improved
survival in patients of breast cancer. At the same time, molecularly-targeted therapy is
also an important strategy. Molecularly-targeted therapeutic strategies is an effective for
breast cancer, and clinical studies have shown its potential molecular targets which
include human epidermal growth factor receptor (HER), mammalian target of
rapamycin (mTOR), and vascular endothelial growth factor (VEGF). However, therapy
for recurrence or metastatic patients is still palliative, and the possibility of inducing
complete cure for breast cancer remains remote. For this reason, many new drugs and
therapeutic strategies have been investigated. Here, we reviewed the up-to-date basic
and clinical developments in molecularly-targeted therapy for breast cancer, focusing
on HER, mTOR, and VEGF.
Breast cancer, human epidermal growth factor receptor (HER),
mammalian target of rapamycin (mTOR), molecularly-targeted therapy, vascular
endothelial growth factor (VEGF).
Multidisciplinary Cancer Treatment Center, Kurume University, 67 Asahi-machi Kurume, 830-0011, Japan.